Open Access Open Access  Restricted Access Subscription or Fee Access

Gene Editing: Rewriting the Life and Consequences

Bhagwan Das Bulchandani


Gene editing is the rational, precise and candid modification of DNA sequences or genes in living cells and organisms, literally for anything and everything possible. Its manifestation ranging from designing disease resistant crops or therapeutic correction of defective genes responsible for myriad of debilitating diseases in human beings to reprogramming of organisms that can produce new sophisticated and potent biologicals. The possible implication of gene editing is wide ranging and sometimes are beyond imagination at least for a common man to comprehend. Not surprisingly, this new revolution has already sparked the interest and enthusiasm of scientists and investors worldwide. Two recently developed technologies, Transcription Activator Like Effector (TALE) nucleases and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) nucleases, made it possible to edit genes within a few weeks, as opposed to several months or years with earlier recombinant technologies. Nevertheless, this highly advanced and sophisticated concept which has the potential to revolutionize the practice of biology for the betterment of world is being seen with certain underlined ethical apprehensions and social anxieties. These must be brought to surface and discussed to reach a consensual decision of how to make it work productively and generate its prolific outcomes. As has repeatedly been said and proved time and again that a sufficiently developed technology is next to miracle.
Keywords: Gene Editing, TALE, CRISPR, Cas9, Double-Stranded Breaks (DSB), Therapeutics, Transgenesis

Cite this Article: B. D. Bulchandani. Gene Editing: Rewriting the Life and Consequences. International Journal of Animal Biotechnology and Applications. 2019; 5(1): 1–10p.

Full Text:



Thakore P.I., Black J.B. and I.B. Hilton. 2016. Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nature Methods, 13 (2):127-37.

Hsu P.D., Lander E.S. and F. Zhang. 2014. Development and applications of CRISPR-Cas9 for genome engineering. Cell, 157(6): 1262-78.

Conko G, Kershen D.L., Miller H. And W.A. Parrott. 2016. A risk-based approach to the regulation of genetically engineered organisms. Nature Biotechnology, 34 (5): 493-503.

Chen, X. and M.A.F.V. Goncalves. 2016. Engineered viruses as genome editing devices. Molecular Therapeutics. 24: 447-457.

Zhu, F. 2014. DICE, an efficient system for interative genomic editing in human pluripotent stem cells. Nucl. Acids Res. 42(5):e34;421-34.

Callaway, E. 2015. DNA mutation clock proves tough to set Nature 519 (7542): 139-40;

Scally, A. 2016. The mutation rate in human evolution and demographic inference. Current Opinion in Genetics and Development, 41: 36-43.

Berg, P. and J. E. Mertz. 2010. Personal reflections on the origins and emergence of recombinant DNA technology. Genetics, 184 (1): 9-17.

Capecchi, M.R. 2005. Gene targeting in mice: functional analysis of the mammalian genome for the twenty first century. Nature Reviews Genetics, 6 (6): 507-12.

Musunuru, K. 2013. Genome editing of human pluripotent stem cells to generate human cellular disease models. Disease Models and Mechanisms, 6 (4): 896-904.

Skarnes, W. C. 2015. Is mouse embryonic stem cell technology obsolete? Genome Biology 16: 109-13.

Paquet, D., Kwart, D. and A. Chen. 2016. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature, 533 (7601): 125-9.

Bibikova, M., Beumer, K., Trautman, J.K. and D. Carroll. 2003. Enhancing gene targeting with designed zinc finger nucleases. Science, 300: 764-79.

Urnov, F.D., Rebar, E.J., Holmes, M.C., Zhang, H.S. and P.D. Gregory. 2010. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 11: 636–646.

Moscou, M.J. and A.J. Bogdanove.2009. A simple cipher governs DNA recognition by TAL effectors. Science 326(5959):1501.

Bogdanove, A.J. and D.F. Voytas. 2011. TAL effectors: Customizable

proteins for DNA targeting. Science, 333: 1843-1846.

Joung, J.K. and J.D. Sander. 2013. TALENs: A widely applicable technology for targeted genome editing. Nat. Rev. Mol. Cell Biol. 14: 49-55.

Jinek, M., Chylinski, K. and I. Fonfara. 2012. A programmable dual RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337 (6096): 816-21.

Boroviak, K., Doe, B. and R. Banerjee. 2016. Chromosome engineering in zygotes with CRISPR/Cas9. Genesis, 54 (2): 78-85.

Cong, L., Ann Ran F. and D. Cox. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science, 339 (6121): 819-23;

Mali, P., Yang, L. and K.M. Esvelt. 2013. RNA-guided human genome engineering via Cas9. Science, 339 (6121): 823-6.

Hettinger, E.C. 1999. Justifying intellectual property. Philosophy and Public Affairs, 18 (1): 31-52.

Calos, M.P. 2016. Phage integrases for genome editing. In Genome Editing: The Next Step in Gene Therapy (eds. Cathomen, T., Hirsch and M., Porteus). Adv. Exp. Med. Biol. 895: 81-91.

Bertoni, C. 2006. Enhancement of plasmid-mediated gene therapy for Duchenne muscular dystrophy by directed plasmid integration. Proc.Natl. Acad. Sci. U.S.A. 103: 419-24.

Loperfido, M. 2016. Bac transposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts. Nucl. Acids Res. 44: 744-60.

Golic, K.G. 2013. RNA-guided nucleases: A new era for engineering the genomes of a model and non-model organisms. Genetics, 195 (2): 303-08.

Dow, L.E. 2015. Modelling disease in vivo with CRISPR/Cas9. Trends in Molecular Medicine, 21 (10): 609-21.

Sander, J.D. and J.K. Joung. 2014. CRISPR-Cas systems for editing, regulating and targeting genomes. Nature Biotechnology, 32 (4): 347-55.

Royal Netherlands Academy of Arts and Sciences. 2016. Genome Editing, Position Paper of the Royal Netherlands Academy of Arts and Sciences. Amsterdam, KNAW.

Lander, E.S. 2016. The heroes of CRISPR. Cell, 164 (1): 18-28.

Ledford, H. 2016. The unsung heroes of CRISPR. Nature, 535 (7612): 342-4.

Smith-Willis, H. and B. San Martín. 2015. Revolutionizing genome editing with CRISPR/Cas9: patent battles and human embryos. Cell and Gene Therapy Insights, 1 (2): 253-62.

Jasanoff, S., Hurlbut, J.B. and K, Saha. 2015. CRISPR democracy: Gene editing and the need for inclusive deliberation. Issues in Science and Technology, 32 (1).


  • There are currently no refbacks.